Elia System Operator SA/NV (0NTU) Receives a Buy from Kepler Capital
In a report released on May 21, Juan Rodriguez from Kepler Capital maintained a Buy rating on Elia System Operator SA/NV (0NTU – Research Report), with a price target of €120.00. The company's shares closed last Wednesday at €93.33.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Rodriguez is a 4-star analyst with an average return of 7.4% and a 59.05% success rate.
Elia System Operator SA/NV has an analyst consensus of Strong Buy, with a price target consensus of €101.96, which is a 9.25% upside from current levels. In a report released on May 6, Morgan Stanley also maintained a Buy rating on the stock with a €120.00 price target.
Based on Elia System Operator SA/NV's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €1.98 billion and a net profit of €254.5 million. In comparison, last year the company earned a revenue of €1.75 billion and had a net profit of €161.9 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The company's shares closed yesterday at $65.05. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. According to TipRanks, Jennings has an average return of 4.6% and a 52.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for PROCEPT BioRobotics with a $80.20 average price target. PRCT market cap is currently $3.32B and has a P/E ratio of -36.24. Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in March 2025, Reza Zadno, the President & CEO of PRCT sold 5,475.00 shares for a total of $312,403.50.
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
Business Insider
2 hours ago
- Business Insider
Kepler Capital Keeps Their Buy Rating on NatWest Group (NWG)
Kepler Capital analyst Nicolas Payen maintained a Buy rating on NatWest Group (NWG – Research Report) on June 4 and set a price target of p535.00. The company's shares closed yesterday at p522.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Payen is a 5-star analyst with an average return of 13.0% and a 67.19% success rate. Payen covers the Financial sector, focusing on stocks such as UBS Group AG, Barclays, and Deutsche Bank AG. NatWest Group has an analyst consensus of Strong Buy, with a price target consensus of p555.82, implying a 6.48% upside from current levels. In a report released on June 4, Citi also maintained a Buy rating on the stock with a £6.30 price target. The company has a one-year high of p537.20 and a one-year low of p300.20. Currently, NatWest Group has an average volume of 35.6M. Based on the recent corporate insider activity of 101 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NWG in relation to earlier this year.
